[{"id":"22b7dd08-d5ab-447e-b0c5-788fa71f7070","acronym":"","url":"https://clinicaltrials.gov/study/NCT01564251","created_at":"2021-01-18T06:37:50.727Z","updated_at":"2024-07-02T16:36:49.584Z","phase":"Phase 1","brief_title":"A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma","source_id_and_acronym":"NCT01564251","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • RG7741"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 03/23/2012","start_date":" 03/23/2012","primary_txt":" Primary completion: 01/11/2018","primary_completion_date":" 01/11/2018","study_txt":" Completion: 01/11/2018","study_completion_date":" 01/11/2018","last_update_posted":"2020-02-25"}]